THE SOLUTION CURAIZON™
INTRODUCTION
CuraData Big Data For Healthcare
- CuraData™ Big Data For Healthcare The enormous amount of unique and valuable data we collect through CuraServe™ finds a home in CuraData™. Our system merges the data we collect through our real-time compliance technologies with the patient's own data.
- Healthcare providers benefit from Big Data if they take a more holistic, patient-centered approach to value; one that focuses equally on health-care spending and treatment outcomes. This is made possible through the data and analytics of Curaizon’s™ data.
- While we track and record patent adherence data and overall demographics, the information that would identify a specific patent, such as name and address, remain anonymous.
- Researchers, academics and pharmaceutical companies access the information as big data in a fully anonymized form.
- CuraData™ plays a primary role in increasing our token’s utility.
WHT IS CURAIZON™?
Curaizon™ is the only company that offers a complete healthcare ecosystem that supports patents by reducing drug non-adherence. The ecosystem includes CuraServe™, CuraData™, and CuraView™ and helps to lower healthcare costs and advance medical research.
- Curaserve
- Curaview
- Curadata
Play video and learn more about Curaizon™
Why Is Our Medical Data So Valuable?
- The total number of potential users of our platform includes all of the patents covered by national health services across the world.
- The reason that our data is so valuable is that it simply doesn’t exist anywhere else. Today, there is no accurate, real-time adherence or behavioral data for patients taking medications.
- Through our advanced data and machine learning analytics, Curaizon™ will deliver technologies that will help speed up drug trials and development; provide information that will dramatically improve patent outcomes while reducing the avoidable waste that occurs as a result of low adherence to medications.
- The societal benefits of our data and technologies is unmatched and will lead to a signifcant demand from pharmaceutical companies and biotech researchers as well as health care services and will lead to patents better understanding their own health.
We’re solving an enormous real-world problem by helping patients take their medications properly
- Every day, millions of people fail to take their medications as prescribed and the resulting personal and financial costs are staggering. Worldwide, non-adherence results in $700 billion in avoidable medical costs.
- The data we create is unique and has enormous value to pharmaceutical companies, researchers and governments.
- Every time a patient uses our CuraServe technology, our data grows in utility and value.
- Curaizon solves the drug non-adherence problem by deploying our technology through national health services. As part of our solution, we collect fully anonymized data about how and when patients take medications.
- CuraTokens™ is the only way to access our data. Tokens can be redeemed to access the data, which will advance medical research, drive down health care costs and save lives.
- The value of a CuraToken™ is based on a real solution to a real problem.
Curaizon™ Ecosystem
TOKEN
CuraToken™ Utility Tokens (CTKN) allow the token holder to access our proprietary and anonymized medical data on the blockchain.
- CuraTokens™ is the only way to access Curaizon’s™ technology.
- CuraToken™ holders can access data which utilizes powerful, predictive analytics, AI and big data in the fight against drug non-adherence.
- CuraTokens™ provides real-time analysis of patient behavior and adherence.
- CuraTokens™ enable the use of blockchain technology to manage authentication, confidentiality, and accountability by allowing individuals to be in control of their data, providing protection, security, and compliance with all upcoming, required regulations, including GDPR.
- CuraTokens™ facilitate partnerships with medical and pharmaceutical organizations through a token reward system.
- CuraToken™ holders know they are saving lives around the world by helping to solve the problem of drug non-adherence.
BY TECHNOLOGY
What does the company do?
We aim to improve drug adherence and bring game-changing benefits to patients and healthcare providers by being the leading supplier of adherence and data solutions worldwide.
What is unique about the company?
Our solution works with patients, their families, and healthcare providers to ensure that patients take their medications as prescribed through a series of outreach tools, supported by predictive modeling tools and behavioral analysis, to increase the rate of drug adherence
What problem does the company solve?
Our CuraServe technology helps ensure that patients take their medicines as prescribed by their doctor. By doing this, we help patients live longer and healthier lives. We also reduce the health care costs that occur when patients fail to take their medications properly.
How do you create value to support your CuraTokens?
Our CuraServe™ technology generates a tremendous amount of unique, real-time data showing how people take their medications that is very valuable to a variety of groups including pharmaceutical companies, medical researchers and biotech companies. CuraTokens™ allow token owners access to the data to make queries. As our solution is rolled out to more and more patients in more and more countries. The more data we generate, the more valuable that CuraTokens™ become.
Who are your target customers?
Curaizon™ sells its adherence (CuraServe™) solutions to national health services around the world. Our end users are the health service’s patients who take any form of medication. We also work with academia, pharmaceutical and biotech industries, as well as other users of data via our CuraData™ solution.
What is your geographic target market?
Curaizon targets countries with national health services. This currently includes 1.4 Billion people and that number is growing.
What are the potentials of the market?
The global cost of non-adherence is over €600 billion each year and results in hundreds of thousands of lives lost prematurely. Adherence for chronic and long-term illness is less than 50%.
CONTACT
Any question? Reach out to us and we’ll get back to you shortly. info@curaizon.com
https://www.facebook.com/curaizonltd
